Votrien

Buy Votrien BRAND beware of counterfeit medications Votrien Pazopanib is a TKI (tyrosine kinase inhibitor)approved by the FDA and European Health authorities for the treatment of metastatic(advanced)kidney cancer or MRCC (Metastatic renal cancer). Trials have showed improved PFS progression free survival (9.2 month compared to 4.3 month) for patients using Votrient Pazopanib 800mg a day Votrient received NCCN (national comprehensive cancer network) Guidelines Category 1 recommendation as first-line therapy for relapsed or Stage IV unresectable RCC of predominant clear cell histology VOTRIENT Profile of A.E (Adverse Events) : Most common AE observed with VOTRIENT were diarrhea, anorexia, vomiting, hypertension, & hair color changes Severe fatigue occurred in 2% of patients; all grades, 19% Severe asthenia occurred in 3% of patients; all grades, 14% Laboratory abnormalities observed with VOTRIENT were ALT and AST increases VOTRIENT inhibits the following proteins: VEGFR 1, 2,3 Vascular endothelial growth factor receptors PDGFR alpha and beta Platelet-derived growth factor receptors α and β FGFR 1, 3 Fibroblast growth factor receptors CKIT Stem cell factor receptor ITK Interleukin-2 receptor inducible T-cell kinase LCK Leukocyte-specific protein tyrosine kinase C-FMS Transmembrane glycoprotein receptor tyrosine kinase Note: IsraMeds also stock the newly approved Inlyta (axitinib) 10mg tabs made by Pfizer BRAND call for prices Also Available are Sutent (sunitinib) Afinitor (everolimus) Nexavar(Sorafenib) among other oncologic medications